Parkinson’s Deep Brain Stimulation (DBS) Cost Calculator
This calculator estimates the out-of-pocket cost of deep brain stimulation (DBS) for Parkinson’s disease (and essential tremor and dystonia) in Korea, and keeps the same pure calculation model as the Korean page for a bilateral non-rechargeable device, a bilateral rechargeable device, a unilateral device, and a stimulator (IPG) replacement. DBS places thin electrodes in a deep brain target (the subthalamic nucleus or globus pallidus for Parkinson’s) and an implanted pulse generator (IPG) under the chest skin to deliver electrical stimulation that controls tremor, rigidity, and slowness. It has been covered by Korean National Health Insurance since about 2005, and Parkinson’s disease is a registered severe-intractable special-case condition, so the figures follow 2026 Korean rules.
Device types and covered fees
A bilateral non-rechargeable DBS is the standard for Parkinson’s: one electrode in each subthalamic nucleus (STN) plus a non-rechargeable pulse generator (IPG). The stimulator and electrode material dominate the bill, so the model uses about KRW 4,000,000 for the procedure, KRW 11,000,000 for the covered non-rechargeable IPG, KRW 2,500,000 per electrode (two electrodes), and a covered ward fee of KRW 150,000 per day, for a covered total near KRW 21,500,000 and a 10 percent special-case self-pay of about KRW 2,150,000.
A bilateral rechargeable DBS uses a costlier IPG (about KRW 18,000,000) that lasts far longer, so the covered total is higher (near KRW 28,500,000) but the battery is replaced much less often. A unilateral DBS uses one electrode for one-sided symptoms. A stimulator (IPG) replacement reuses the existing brain electrodes and changes only the chest generator, so the electrode cost is zero and the stay is short.
- Covered electrode material is about KRW 2,500,000 per lead; a replacement reuses the electrodes (zero lead cost).
- The implanted pulse generator (IPG) is the largest part of the covered total.
- Bilateral (two electrodes) is standard for Parkinson’s; unilateral suits one-sided symptoms.
- A rechargeable IPG costs more up front but is replaced far less often.
Parkinson’s special case is 10 percent, not 5 percent
The Ministry of Health and Welfare notice on special copay calculation (No. 2026-101, effective 2026-05-01) lists Parkinson’s disease (ICD G20) under Annex 4-2, severe-intractable special-case conditions, with special code V124. When registered, the covered self-pay drops from the ordinary inpatient 20 percent to 10 percent. Some hospital pages say “5 percent,” but that is a confusion with the cancer, cardiac, cerebrovascular, and severe-burn list (Annex 3, 5 percent); Parkinson’s is a severe-intractable condition at 10 percent.
Crucially, unlike the cancer/cardiac special case (up to 30 days from surgery), the Parkinson’s severe-intractable special case applies for 5 years from registration and covers the whole related benefit course — the DBS surgery, medication, outpatient visits, and programming. Because it is a chronic, progressive disease, that 5-year coverage keeps the real burden low over time. Note that, unlike the automatically applied cancer/cardiac special case, the rare/severe-intractable special case requires a registration application, so confirm registration at the hospital admissions desk after diagnosis.
Rechargeable vs non-rechargeable: compare lifetime cost
The core difference between the two IPG types is battery life and therefore replacement frequency. A non-rechargeable battery lasts about 3-5 years and must be replaced with a generator-replacement surgery each time, while a rechargeable one lasts about 9-15 years and is replaced rarely. On up-front cost alone the non-rechargeable device is cheaper, but over a long horizon the replacement surgeries add up.
The calculator computes a 15-year lifetime self-pay for each type at the current benefit rate — the non-rechargeable initial cost plus its expected replacements, versus the rechargeable initial cost plus its (far fewer) replacements — so you can see how the higher up-front cost of a rechargeable device can be overtaken over time. A rechargeable device does require the patient or a caregiver to charge it regularly, so weigh cost against the ability to manage charging.
Battery replacement, ceiling, indemnity, and tax credit
When the battery runs out, a stimulator (IPG) replacement reuses the brain electrodes and changes only the chest generator, with a shorter stay than the first implant; if the special case is still active, the replacement is also 10 percent. The calculator projects the expected battery life and the estimated replacement self-pay.
The 2026 annual out-of-pocket ceiling ranges from about KRW 900,000 (income decile 1) to KRW 8,430,000 (decile 10) and refunds covered self-pay above the cap, usually the following August. DBS is reimbursed as inpatient medical expense by private indemnity insurance (the ceiling-refunded amount is not double-paid, and upper-grade room surcharges are usually reimbursed only up to 50 percent). The Korean medical expense tax credit (Income Tax Act Article 59-4) refunds 15 percent of expense above 3 percent of salary; for a registered severe-disease patient (V124) the usual KRW 7,000,000 cap does not apply (Enforcement Decree Article 118-5), so even large self-pay is fully creditable.
How to read the result
Enter the device type (bilateral non-rechargeable, bilateral rechargeable, unilateral, or IPG replacement), the indication (Parkinson’s, essential tremor, or dystonia), whether the special case is registered, stay days, hospital level, insurance type, income decile, private indemnity generation, and salary. The result shows covered and non-covered self-pay, the special-case 10 percent versus 20 percent comparison, the rechargeable versus non-rechargeable 15-year lifetime cost, the battery replacement projection, the ceiling refund, and the final cost after indemnity and tax credit.
This is a cost-planning estimate based on 2026 Korean rules, not medical advice. Public single-price tables for DBS do not exist, so the device and total figures are defensible market-estimate ranges that vary with hospital, device brand, electrode count, and patient condition; exact benefit codes and fees should be confirmed with the hospital and the Health Insurance Review and Assessment Service. DBS coverage also requires meeting clinical criteria (for Parkinson’s, levodopa responsiveness with persistent motor complications). Confirm details with the treating neurosurgeon, the insurer, and the hospital quote.
This calculator is based on Korean rules (2026 National Health Insurance covered fees, the Parkinson’s severe-intractable special case V124 at 10 percent for 5 years, the annual out-of-pocket ceiling, and Income Tax Act Article 59-4 medical expense tax credit with the severe-disease cap exemption). Figures are planning estimates, not medical advice, an insurer decision, or a hospital quote.